CHICAGO — Max S. Topp, MD, head of hematology at University Hospital of Wuerzburg, Germany, spoke with HemOnc Today at ASCO Annual Meeting about a study that evaluated the effects of earlier steroid use by patients who underwent chimeric antigen receptor therapy.
The ZUMA-1 trial included patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel (Yescarta, Kite Pharma), an autologous anti-CD19 CAR T-cell therapy.
Data from 21 patients included in a safety expansion cohort showed early use of steroids may help reduce incidence of severe cytokine release syndrome and neurologic events without affecting response rates, Topp said.
The full dataset will be presented in December at ASH Annual Meeting and Exposition, Topp said. – by Mark Leiser
Reference: Topp MS, et al. Abstract 7558. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.
Disclosure: Topp reports consultant/advisory roles with, research funding from, and travel, accommodations or expenses from Amgen, Kite Pharma, Regeneron and Roche.